{"id":7961,"date":"2026-05-07T09:41:28","date_gmt":"2026-05-07T07:41:28","guid":{"rendered":"https:\/\/value-dossier.com\/?p=7961"},"modified":"2026-05-07T09:41:39","modified_gmt":"2026-05-07T07:41:39","slug":"deep-dive-price-volume-model-%c2%a7130b","status":"publish","type":"post","link":"https:\/\/value-dossier.com\/en\/deep-dive-price-volume-model-%c2%a7130b\/","title":{"rendered":"Deep Dive: Price-Volume Model (\u00a7130b)"},"content":{"rendered":"\n<section class=\"wrap_outer textblock\">\n    <div class=\"wrap_inner\">\n\n        <div class=\"okd-text\">\n            <p>The price-volume regulation shall no longer be subject to arbitration. The default mechanism kicks in if no agreement between the pharmaceutical company and the statutory health insurances is reached and adjusts the reimbursement amount annually (starting in the third calendar year after launch) using a clear formula:<\/p>\n<p>\u27a1\ufe0f <strong>Revenue growth vs. reference year \u00d7 1.7% + volume-based surcharge for revenues &gt; 100M \u20ac (1% \u00d7 revenue \/ 100M \u20ac)<\/strong><\/p>\n<p><strong>Implications:<\/strong><\/p>\n<ul>\n<li><strong>Discounts start in the fourth year after initial market launch:<\/strong><br \/>\nThe calculation is based on the difference between the previous calendar year and the reference year (= first calendar year after market launch = Year 2 if launched in Year 1). Therefore, revenue from at least one additional calendar year following the reference year is required to calculate the discount.<\/li>\n<li><strong>Revenue in the reference year influences future price reductions:<\/strong><br \/>\nIf the revenue exceeds the reference year\u2019s level, sales volume (sold units) must continue to increase to maintain the revenue. Otherwise, the reimbursement amount and revenu will decline while sales volume remains constant (plateau phase).<\/li>\n<li><strong>The launch date can affect revenue in the reference year:<\/strong><br \/>\nThe launch price applies for the first 6 months, and the negotiated reimbursement amount applies starting in month 7. Therefore, both the Market Update in Year 1 and the respective price are decisive for the reference year.<\/li>\n<\/ul>\n<p><strong>Conclusion:<\/strong><br \/>\nThe default Price-Volume Model is largely consistent with the Arbitration Board\u2019s previous decisions. Companies may agree on different arrangements; however, these will no longer be subject to arbitration.<\/p>\n<p><strong>Assumptions for the presented price simulation:<\/strong><\/p>\n<ul>\n<li>The product was launched on the German market sometime during Year 1.<\/li>\n<li>Year 2 is the first full calendar year following the market launch and thus serves as the reference year.<\/li>\n<li>To calculate the price reduction, the difference vs. Year 2 is required. Therefore, the discount occurs for the first time in Year 4 and is based on the difference between Year 3 vs. Year 2.<\/li>\n<li>The negotiated reimbursement amount is 20% below the launch price and already applies in Year 2.<\/li>\n<li>The curves represent the relative trend and not the absolute figures.<\/li>\n<li>The relative trend is shown for both, products with revenue &lt; \u20ac100 million and products with revenue &gt;100M \u20ac. In both cases, the reference year is below 100M \u20ac.<\/li>\n<li>The discount in percent (Year 10 vs. Year 2), amounting to 8.9% (&lt;100M \u20ac) and 21.2% (&gt;100M \u20ac), are based on exemplary data. The actual magnitude of the price reductions depends on the product-specific situation.<\/li>\n<\/ul>\n        <\/div>\n\n    <\/div>\n<\/section>","protected":false},"excerpt":{"rendered":"","protected":false},"author":2,"featured_media":7962,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[1],"tags":[],"class_list":["post-7961","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nicht-kategorisiert"],"acf":[],"_links":{"self":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7961","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/comments?post=7961"}],"version-history":[{"count":2,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7961\/revisions"}],"predecessor-version":[{"id":7964,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/posts\/7961\/revisions\/7964"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media\/7962"}],"wp:attachment":[{"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/media?parent=7961"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/categories?post=7961"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/value-dossier.com\/en\/wp-json\/wp\/v2\/tags?post=7961"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}